Citation

BibTex format

@article{Fidler:2023:cid/ciac796,
author = {Fidler, S and Fox, J and Tipoe, T and Longet, S and Tipton, T and Abeywickrema, M and Adele, S and Alagaratnam, J and Ali, M and Aley, PK and Aslam, S and Balasubramanian, A and Bara, A and Bawa, T and Brown, A and Brown, H and Cappuccini, F and Davies, S and Fowler, J and Godfrey, L and Goodman, AL and Hilario, K and Hackstein, CP and Mathew, M and Mujadidi, YF and Packham, A and Petersen, C and Plested, E and Pollock, KM and Ramasamy, MN and Robinson, H and Robinson, N and Rongkard, P and Sanders, H and Serafimova, T and Spence, N and Waters, A and Woods, D and Zacharopoulou, P and Barnes, E and Dunachie, S and Goulder, P and Klenerman, P and Winston, A and Hill, AVS and Gilbert, SC and Carroll, M and Pollard, AJ and Lambe, T and Ogbe, A and Frater, J},
doi = {cid/ciac796},
journal = {Clinical Infectious Diseases},
pages = {201--209},
title = {Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV},
url = {http://dx.doi.org/10.1093/cid/ciac796},
volume = {76},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: People with HIV on antiretroviral therapy with good CD4 T cell counts make effective immune responses following vaccination against SARS-CoV-2. There are few data on longer term responses and the impact of a booster dose. METHODS: Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed twelve months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µl. Immune responses to the ancestral strain and variants of concern were measured by anti-spike IgG ELISA, MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, Activation Induced Marker (AIM) assay and T cell proliferation. FINDINGS: 54 participants received two doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) one year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titres (MSD), ACE-2 inhibition and IgG ELISA results were significantly higher compared to Day 182 titres (P < 0.0001 for all three). SARS-CoV-2 specific CD4+ T cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4 + and CD8+ T cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. CONCLUSIONS: In PWH receiving a third vaccine dose, there were significant increases in B and T cell immunity, including to known VOCs.
AU  - Fidler,S
AU  - Fox,J
AU  - Tipoe,T
AU  - Longet,S
AU  - Tipton,T
AU  - Abeywickrema,M
AU  - Adele,S
AU  - Alagaratnam,J
AU  - Ali,M
AU  - Aley,PK
AU  - Aslam,S
AU  - Balasubramanian,A
AU  - Bara,A
AU  - Bawa,T
AU  - Brown,A
AU  - Brown,H
AU  - Cappuccini,F
AU  - Davies,S
AU  - Fowler,J
AU  - Godfrey,L
AU  - Goodman,AL
AU  - Hilario,K
AU  - Hackstein,CP
AU  - Mathew,M
AU  - Mujadidi,YF
AU  - Packham,A
AU  - Petersen,C
AU  - Plested,E
AU  - Pollock,KM
AU  - Ramasamy,MN
AU  - Robinson,H
AU  - Robinson,N
AU  - Rongkard,P
AU  - Sanders,H
AU  - Serafimova,T
AU  - Spence,N
AU  - Waters,A
AU  - Woods,D
AU  - Zacharopoulou,P
AU  - Barnes,E
AU  - Dunachie,S
AU  - Goulder,P
AU  - Klenerman,P
AU  - Winston,A
AU  - Hill,AVS
AU  - Gilbert,SC
AU  - Carroll,M
AU  - Pollard,AJ
AU  - Lambe,T
AU  - Ogbe,A
AU  - Frater,J
DO  - cid/ciac796
EP  - 209
PY  - 2023///
SN  - 1058-4838
SP  - 201
TI  - Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV
T2  - Clinical Infectious Diseases
UR  - http://dx.doi.org/10.1093/cid/ciac796
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36196614
UR  - https://academic.oup.com/cid/article/76/2/201/6748267
VL  - 76
ER  -
Download